Introduction 28
Anorexia nervosa (AN) is a serious mental illness characterized by difficulties consuming 29 sufficient calories to maintain body weight in conjunction with disturbances in self-perception. 30 Although this disease often begins in adolescents and young adulthood, the course of disease is 31 prolonged and outcomes are poor (1) . In examination of treatment outcomes in partial hospitalization 32 and intensive outpatient settings, individuals with AN had worse outcomes than individuals with 33 bulimia nervosa, binge eating disorder, and other specified feeding or eating disorder (2). 34
Additionally, a recent meta-analysis showed that treatment changed only short-term weight outcomes 35 but did not significantly impact either short-term or long-term psychosocial outcomes or long-term 36 recovery (3). 37 AN has a relapse rate of approximately 31%, with the highest risk in the first year to two 38 years post-treatment (4). The dropout rate from outpatient treatment for AN is estimated to range 39 from 20-40% (5). Qualitative research on recovered women highlights the importance of 40 psychosocial support as part of recovery (6). However, there is little evidence that defines what is 41 optimal outpatient treatment for adults with AN, and minimal data describing even the types of 42 treatment utilized in the community in the United States. Most longitudinal work in adults has 43 focused on assessment of changes in clinical symptoms (1, 7) or follow-up of patients after specific 44 types of interventions (8, 9). 45
Here, we evaluated the symptoms and types of treatments utilized by women with AN in Texas. 46 All participants were diagnosed with AN previously, and were originally recruited to participate in 47 studies comparing women with AN currently and those in long-term weight recovery following AN. 48 Previously, we reported on the re-assessed clinical status of these participants two to six years after 49 original measures were collected, comparing clinical and cognitive symptoms at baseline and outcome 50 in participants with continued symptoms, participants whose symptoms had remitted since initial 51 assessments, and participants who remained in sustained recovery (7) . Here, we report and compare 52 the types of treatment obtained by these subjects at the most severe stage of their eating disorder as 53 well as during the time period since participating in the study. We hypothesized that there would be 54 less utilization of outpatient treatment providers amongst the women that relapsed and persisted with 55 disease relative to those that recovered. 56
Methods 57

Participants 58
Forty-six women ages 20-61 (M = 30.3, SD = 8.61) participated. All subjects had completed 59 baseline measures as part of one or more of three previous studies (enrollment period was 2011-2014) 60 including both currently-ill (AN-C) and weight-recovered (AN-WR) women with AN (10-12). For all 61 studies, the AN-C group included women who had met DSM-IV criteria for AN within the previous 62 six months whereas the AN-WR group required women to have maintained a body mass index (BMI) 63 > 19 for at least 12 months despite having met DSM-IV criteria for AN in their lifetime. In addition, 64 the AN-WR participants could not have met DSM-IV criteria for bulimia nervosa in the last two years. 65
The studies were conducted in overlapping time periods; many participants were in more than one 66 study, with the variation resulting from subject preferences and safety concerns related to participation 67 in magnetic resonance imaging, blood draws, and genetic analyses. 
Statistical analysis 102
Statistical analyses were conducted using the IBM Statistical Package for Social Sciences 103 (SPSS; v.23). To determine differences between groups, separate one-way analysis of variance 104 (ANOVAs) were conducted on continuous data. Post hoc pairwise comparisons were conductedusing a Bonferroni correction for multiple comparisons. Categorical and dichotomous (yes/no) data 106 were analyzed by Chi-square analyses. 107
Results 108
Participants 109
As previously reported, amongst the AN-C group, 17 participants remained ill (AN-CC) and 110 11 achieved recovery from a baseline ill status (AN-CR), a recovery rate of 39%. In addition, all 18 111 of the AN-WR group remained weight-recovered at follow up (AN-WS). There were no differences 112 in the distributions of subtypes of AN by group (AN binge-purge/restricting, AN-CC 9/8, AN-CR 113 5/6, AN-WS 11/7; X 2 (2) = 0.67, p = 0.71, V = 0.12). 114
The AN-CR group had a later age of onset than the AN-WS (age of onset in years, AN-CC, 
Severe-period symptoms and treatments 121
There were no differences in the clinical symptoms or treatments utilized in the worst period 122 of the disease for any of the groups (Table 1) . Eating disorder symptoms were considered most 123 severe for all subjects on average at 22.6 years, and the lowest BMI was similar across all subjects 124 (mean lowest BMI 15.32). Across all groups, 43.6% of subjects reported binge-eating behaviors, and 125 50% reported purging symptoms in the severe period. 84.8% of the subjects had comorbid depression 126 and 82.6% had comorbid anxiety. Problems with alcohol and substance abuse were less prevalent 127 across the sample, with 21.7% of subjects reporting an alcohol use disorder and 10.9% reporting 128 substance abuse. No differences in the types of intensive treatment utilized following that severe-129 period were observed across the 3 groups, with 43.5% utilizing inpatient or residential treatments, 130 41.3% in partial hospital programs, 39.1% in intensive outpatient. 131 132
Follow-up period symptoms and treatments 133
Few differences were observed in the types and amount of care obtained from clinical 134 providers in the follow-up period between initial participation in the study and returning for the 135 follow-up measures (Table 3) . Some members in all groups attended inpatient, residential or partial 136 hospital eating disorder programs (AN-CC, 47%, AN-CR, 36%, AN-WS, 17%). The three subjects in 137 the AN-WS group that required a higher level of care did so for escalating ED symptoms consistent 138 with having developed and then recovered from bulimia nervosa during the follow-up period. The 139 only significant difference was related to intensive outpatient treatment programs, which were most 140 heavily utilized by those currently ill with AN (AN-CC, 53%, AN-CR, 9%, AN-WR, 6%, X 2 (2) = 141 12.53, p = 0.002). 142
In 
Medications and medical complications 150
In this retrospective study, virtually no participants were able to recall either the duration or 151 names of all psychoactive medications taken. Many reported using medications while in 152 inpatient/residential treatment programs but stopping them days or weeks after discharge for a wide 153 variety of reasons (forgot to pick up, did not have a refill, did not think it was helpful). Because of 154 this limited recall, subjects were grouped into those that took any psychoactive medication regularly 155 for 3 months or longer versus those that did not. All participants that took a medication for more than 156 three months appeared confident about their behavior. With these limits, no differences in medication 157 use were seen across the three groups ( AN participants between beginning and end of treatment, weight was not improved at follow-up, and 207 psychological changes were not observed at either time point. We previously reported that this cohort 208 had no changes longitudinally in body shape questionnaire, anxiety, or self-esteem, although 209 depression and externalizing bias did change over time across groups (7). Another novel finding is 210 that all groups of patients reported that the most severe time-period for eating disorder 211 symptomatology was in their early twenties, potentially identifying a specific high-risk time period of 212 emerging adulthood that could be targeted by increased psychosocial supports or clinical monitoring 213 for eating disorder symptoms. 214
Another potential gap in the treatment of AN identified here is in the recognition and 215 treatment of the many medical complications and problems related to development or progression of 216 the disorder. More of the AN-CC group reported significant medical complications from their disease 217 than those in both the AN-CR and AN-WR groups. These medical complications included 218 gastrointestinal disturbances (gastroesophageal reflux disorder, irritable bowel disorder, 219 gastroparesis) as well as problems from chronic malnutrition (osteopenia, anemia) and purging 220 behaviors (orthostatic hypotension, electrolyte abnormalities). The presence of medical complications 221 of AN may provide a better severity specifier more closely related to course of illness than 222 psychiatric symptoms or body mass index alone, but few researchers examining the progress of 223 eating disorder patients include assessments of medical health and comorbidities. Individuals with 224 medical complications of the disease might also be less responsive to existing treatments for AN and 225 related psychiatric comorbidities. It is particularly concerning that despite the increased presence of 226 medical complications, the AN-CC group was no more likely to have a primary care provider than 227 the other two groups. This may be related to the growing difficulty in securing a primary care 228 provider in the United States (23). A multidisciplinary team that includes a primary care provider 229 cognizant of the medical complications and their treatment may be of particular benefit. 230
This study has many limitations. This was a small sample of individuals with AN, and treatment 231 utilization was based on retrospective report of the patient. Because attending treatment programs 232 often results in substantial disruptions of one's life, recall related to the higher levels of care may be 233 more accurate than the duration one worked with an outpatient therapist, psychiatrist or dietitian. 234
External documentation, exam, or lab work to assess the presence or absence of medical 235 complications for all participants was not possible. The study was based on DSM-IV criteria for AN 236 rather than DSM-5 as the studies began before DSM-5 was published; given that the stringency for 237 AN was actually reduced in DSM-5, all subjects meet those criteria as well. Clinical, cognitive, 238 neural and genetic data from these subjects has been previously published, but information about 239 their severe periods of illness and clinical utilization has not been reported previously. Larger studies 240 that prospectively monitor AN overtime including evaluation of medical complications of the disease 241 in concert with clinical outcome are needed. 242 243 .70 * Subjects were grouped into those that took any psychoactive medication regularly for 3 months or 250 longer versus those that did not; Significant differences are in bold. 251
